Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Cassell A, Yunusa B, Jalloh M, et al. Management of advanced and metastatic prostate cancer: a need for a sub-saharan guideline. J Oncol. 2019;2019:1785428. doi:10.1155/2019/1785428
   PubMed Web of Science ®Google Scholar
• Horwich A, Parker C, Kataja V; ESMO Guidelines Working Group. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):76–78. doi:10.1093/annonc/mdp135
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network: NCCN clinical prastice guidelines in oncology (NCCN Guidelines®): prostate cancer V.2.2021. National Comprehensive Cancer Network, Inc. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459. Accessed July 29, 2022.
   Google Scholar
• Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497–506. doi:10.2217/fon.11.23
   Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. doi:10.1056/NEJMoa041318
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245. doi:10.1200/JCO.2007.12.4008
   PubMed Web of Science ®Google Scholar
• Cho H-J, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials. 2011;32(29):7181–7190. doi:10.1016/j.biomaterials.2011.06.028
   PubMed Web of Science ®Google Scholar
• Tanaudommongkon I, Tanaudommongkon A, Prathipati P, Nguyen JT, Keller ET, Dong X. Curcumin nanoparticles and their cytotoxicity in docetaxel-resistant castration-resistant prostate cancer cells. Biomedicines. 2020;8(8):253. doi:10.3390/biomedicines8080253
   Web of Science ®Google Scholar
• Barani M, Sabir F, Rahdar A, Arshad R, Kyzas GZ. Nanotreatment and nanodiagnosis of prostate cancer: recent updates. Nanomaterials. 2020;10(9):1696. doi:10.3390/nano10091696
   Web of Science ®Google Scholar
• Yan J, Wang Y, Zhang X, Liu S, Tian C, Wang H. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv. 2016;23(5):1757–1762. doi:10.3109/10717544.2015.1069423
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lei BH, Zou Q, Zhu QY, Lu ZJ, Wang Y. 张扬, 雷博涵, 邹青, 朱清毅, 卢子杰, 汪悦.中西医结合治疗去势抵抗性前列腺癌的疗效观察.中华男科学杂志. [Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer]. Zhonghua Nan Ke Xue. 2017;23(10):922–927. Chinese.
   Google Scholar
• Markowitsch SD, Juetter KM, Schupp P, et al. Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis. Cancers. 2021;13(4):882. doi:10.3390/cancers13040882
   Web of Science ®Google Scholar
• Fu W, Hong Z, You X, et al. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer. Biomed Pharmacother. 2019;118:109374. doi:10.1016/j.biopha.2019.109374
   Web of Science ®Google Scholar
• Singh SP, Wahajuddin YDK, Rawat P, Maurya R, Jain GK. Quantitative determination of formononetin and its metabolite in rat plasma after intravenous bolus administration by HPLC coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(3–4):391–397. doi:10.1016/j.jchromb.2009.12.010
   Web of Science ®Google Scholar
• Wang AL, Li Y, Zhao Q, Fan LQ. Formononetin inhibits colon carcinoma cell growth and invasion by microRNA-149-mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways. Mol Med Rep. 2018;17(6):7721–7729. doi:10.3892/mmr.2018.8857
   Web of Science ®Google Scholar
• Jarred RA, Keikha M, Dowling C, et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1689–1696.
   PubMed Web of Science ®Google Scholar
• Ong SKL, Shanmugam MK, Fan L, et al. Focus on formononetin: anticancer potential and molecular targets. Cancers. 2019;11(5):611. doi:10.3390/cancers11050611
   Web of Science ®Google Scholar
• Ye Y, Hou R, Chen J, et al. Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation. Horm Metab Res. 2012;44(4):263–267. doi:10.1055/s-0032-1301922
   PubMed Web of Science ®Google Scholar
• Huang WJ, Bi LY, Li ZZ, Zhang X, Ye Y. Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the IGF-1/IGF-1R signaling pathway. Pharm Biol. 2013. PMID: 24359236. doi:10.3109/13880209.2013.842600
   Web of Science ®Google Scholar
• Liu XJ, Li YQ, Chen QY, Xiao SJ, Zeng SE. Up-regulating of RASD1 and apoptosis of DU-145 human prostate cancer cells induced by formononetin in vitro. Asian Pac J Cancer Prev. 2014;15(6):2835–2839. doi:10.7314/APJCP.2014.15.6.2835
   PubMedGoogle Scholar
• Li T, Zhao X, Mo Z, et al. Formononetin promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells. Cell Physiol Biochem. 2014;34(4):1351–1358. doi:10.1159/000366342
   Google Scholar
• Yan J, Wang Y, Jia Y, et al. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer. Biomed Pharmacother. 2017;88:374–383. doi:10.1016/j.biopha.2016.12.138
   PubMed Web of Science ®Google Scholar
• Souchek JJ, Wojtynek NE, Payne WM, et al. Hyaluronic acid formulation of near infrared fluorophores optimizes surgical imaging in a prostate tumor xenograft. Acta Biomater. 2018;75:323–333. doi:10.1016/j.actbio.2018.06.016
   PubMed Web of Science ®Google Scholar
• Qu Z, Ren Y, Shen H, Wang H, Shi L, Tong D. Combination therapy of metastatic castration-recurrent prostate cancer: hyaluronic acid decorated, cabazitaxel-prodrug and orlistat co-loaded nano-system. Drug Des Devel Ther. 2021;15:3605–3616. doi:10.2147/DDDT.S306684
   Web of Science ®Google Scholar
• Jin Y, Wang Y, Liu X, et al. Synergistic combination chemotherapy of lung cancer: cisplatin and doxorubicin conjugated prodrug loaded, glutathione and pH sensitive nanocarriers. Drug Des Devel Ther. 2020;14:5205–5215. doi:10.2147/DDDT.S260253
   PubMed Web of Science ®Google Scholar
• Chen G, Zhang Y, Deng H, Tang Z, Mao J, Wang L. Pursuing for the better lung cancer therapy effect: comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines. Biomed Pharmacother. 2020;125:109988. doi:10.1016/j.biopha.2020.109988
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Z, Liu D, Liu C, Juan Z, Zhang N. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm. 2011;413(1–2):194–201. doi:10.1016/j.ijpharm.2011.04.023
   PubMed Web of Science ®Google Scholar
• Wang C, Su L, Wu C, Wu J, Zhu C, Yuan G. RGD peptide targeted lipid-coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma. Drug Dev Ind Pharm. 2016;42(12):1938–1944. doi:10.1080/03639045.2016.1185435
   PubMed Web of Science ®Google Scholar
• Dong Z, Guo J, Xing X, Zhang X, Du Y, Lu Q. RGD modified and PEGylated lipid nanoparticles loaded with puerarin: formulation, characterization and protective effects on acute myocardial ischemia model. Biomed Pharmacother. 2017;89:297–304.
   PubMed Web of Science ®Google Scholar
• Guo J, Xing X, Lv N, et al. Therapy for myocardial infarction: in vitro and in vivo evaluation of puerarin-prodrug and tanshinone co-loaded lipid nanoparticulate system. Biomed Pharmacother. 2019;120:109480. doi:10.1016/j.biopha.2019.109480
   PubMed Web of Science ®Google Scholar
• Liu C, Liu F, Feng L, Li M, Zhang J, Zhang N. The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials. 2013;34(10):2547–2564. doi:10.1016/j.biomaterials.2012.12.038
   PubMed Web of Science ®Google Scholar
• Liang Z, Li J, Zhu B. Lung cancer combination treatment: evaluation of the synergistic effect of cisplatin prodrug, vinorelbine and retinoic acid when co-encapsulated in a multi-layered nano-platform. Drug Des Devel Ther. 2020;14:4519–4531. doi:10.2147/DDDT.S251749
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem. 1981;115(1):207–216. doi:10.1111/j.1432-1033.1981.tb06218.x
   PubMedGoogle Scholar
• Fan X, Wang T, Ji Z, Li Q, Shen H, Wang J. Synergistic combination therapy of lung cancer using lipid-layered cisplatin and oridonin co-encapsulated nanoparticles. Biomed Pharmacother. 2021;141:111830. doi:10.1016/j.biopha.2021.111830
   PubMed Web of Science ®Google Scholar
• Zou W, Liu C, Chen Z, Zhang N. Studies on bioadhesive PLGA nanoparticles: a promising gene delivery system for efficient gene therapy to lung cancer. Int J Pharm. 2009;370(1–2):187–195. doi:10.1016/j.ijpharm.2008.11.016
   Web of Science ®Google Scholar
• Yu W, Liu C, Ye J, Zou W, Zhang N, Xu W. Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery. Nanotechnology. 2009;20(21):215102. doi:10.1088/0957-4484/20/21/215102
   PubMed Web of Science ®Google Scholar
• Hong Y, Che S, Hui B, Wang X, Zhang X, Ma H. Combination therapy of lung cancer using layer-by-layer cisplatin prodrug and curcumin co-encapsulated nanomedicine. Drug Des Devel Ther. 2020;14:2263–2274. doi:10.2147/DDDT.S241291
   PubMed Web of Science ®Google Scholar
• Rahman M, Almalki WH, Afzal O, et al. Cationic solid lipid nanoparticles of resveratrol for hepatocellular carcinoma treatment: systematic optimization, in vitro characterization and preclinical investigation. Int J Nanomedicine. 2020;15:9283–9299. doi:10.2147/IJN.S277545
   PubMed Web of Science ®Google Scholar
• Tan S, Wang G. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. Drug Des Devel Ther. 2017;11:3519–3529. doi:10.2147/DDDT.S151422
   PubMed Web of Science ®Google Scholar
• Chandratre SS, Dash AK. Multifunctional nanoparticles for prostate cancer therapy. AAPS PharmSciTech. 2015;16(1):98–107. doi:10.1208/s12249-014-0202-z
   Web of Science ®Google Scholar
• Hong Y, Che S, Hui B, et al. Lung cancer therapy using doxorubicin and curcumin combination: targeted prodrug based, pH sensitive nanomedicine. Biomed Pharmacother. 2019;112:108614. doi:10.1016/j.biopha.2019.108614
   PubMed Web of Science ®Google Scholar
• Zhang R, Ru Y, Gao Y, Li J, Mao S. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. Drug Des Devel Ther. 2017;11:2631–2642. doi:10.2147/DDDT.S143047
   PubMed Web of Science ®Google Scholar
• Song Z, Shi Y, Han Q, Dai G. Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles. Biomed Pharmacother. 2018;105:18–26. doi:10.1016/j.biopha.2018.05.095
   PubMed Web of Science ®Google Scholar
• Wang J. Combination treatment of cervical cancer using folate-decorated, pH-sensitive, carboplatin and paclitaxel co-loaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther. 2020;14:823–832. doi:10.2147/DDDT.S235098
   PubMed Web of Science ®Google Scholar
• Cui T, Zhang S, Sun H. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. Oncol Rep. 2017;37(2):1253–1260.
   PubMed Web of Science ®Google Scholar
• Xu G, Chen Y, Shan R, Wu X, Chen L. Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer. Biomed Pharmacother. 2018;99:354–362. doi:10.1016/j.biopha.2018.01.062
   Web of Science ®Google Scholar